Wanbury Limited (WANBURY) AI Stock Analysis

• Market Cap: ₹7.27B
• Dividend Yield: N/A
• Average Volume (3M): 8.26K
• Price to Earnings (P/E): 13.6
• Beta (1Y): 2.37
• Revenue Growth: 8.92%
• EPS Growth: -5.56%
• Country: IN
• Employees: 1,491
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.62
• Shares Outstanding: 34,892,000
• 10 Day Avg. Volume: 8,584
• 30 Day Avg. Volume: 8,255
• PEG Ratio: -0.63
• Price to Book (P/B): 14.81
• Price to Sales (P/S): 1.46
• P/FCF Ratio: -38.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: ₹222.00 ▼(-5.69% Downside)

The score is driven primarily by improving financial performance (revenue and margin recovery) but is capped by leverage and negative free cash flow. Technicals remain mixed with broader-trend weakness (below key longer-term averages and negative MACD), while valuation is reasonable with a moderate P/E but no dividend support.

Positive Factors

Revenue and margin recovery

Sustained improvements in revenue and core margins indicate the business is regaining pricing power and operational efficiency. Over 2–6 months this supports durable cash generation potential and validates execution on product mix and cost controls, underpinning recovery momentum.

Restored shareholders' equity

The shift from negative to positive equity materially reduces insolvency risk and improves the firm’s balance sheet resilience. This structural repair enhances capacity to raise debt/equity on better terms and supports longer-term investment or refinancing options over multiple quarters.

Improving operating cash conversion

A stronger operating cash flow profile, with efficient conversion versus net income, points to better working capital management and recurring cash generation. This durable improvement supports funding of operations and reduces reliance on short-term financing if sustained.

Negative Factors

High leverage

Elevated leverage structurally raises interest obligations and reduces strategic flexibility. Over the medium term it constrains capex, M&A, and R&D spending, increases refinancing risk if rates rise, and leaves less buffer for cyclical industry shocks or regulatory compliance costs.

Persistently negative free cash flow

Ongoing negative free cash flow forces reliance on external financing or asset sales to fund growth and debt service. Structurally, this limits ability to deleverage, pay dividends, or invest in capacity expansion without consistent and sustained cash-flow improvement.

Earnings instability / negative EPS growth

Negative EPS growth and fluctuating net margins signal inconsistent profitability and operational volatility. Over a multi-month horizon this undermines reinvestment capacity, weakens stakeholder confidence, and complicates long-term planning for portfolio expansion or entry into regulated export markets.

Wanbury Limited Business Overview & Revenue Model

Company Description

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.

How the Company Makes Money

Wanbury generates revenue primarily through the sale of pharmaceutical products, including generics and specialty drugs, to healthcare providers, pharmacies, and distributors. The company has established key revenue streams through its extensive product portfolio and a strong distribution network that allows it to reach a wide customer base. Additionally, Wanbury's revenue is bolstered by strategic partnerships and collaborations with other pharmaceutical firms, which can include joint ventures for research and development, as well as licensing agreements that expand its market reach and product offerings. The company also benefits from export sales, as it supplies its products to international markets, thereby diversifying its income sources and enhancing its overall financial performance.

Wanbury Limited Financial Statement Overview

Summary

Revenue and operating margins (gross/EBIT/EBITDA) are improving, supporting a recovery narrative, but high leverage and persistently negative free cash flow reduce financial flexibility despite better operating cash flow.

Income Statement

Wanbury Limited shows a strong recovery in revenue with a noticeable growth rate from 2023 to 2025. The gross profit and EBIT margins have improved, indicating enhanced operational efficiency. However, net profit margin is fluctuating, showing some instability in profitability. Despite this, the overall trend appears positive with EBITDA margins also showing strength.

Balance Sheet

The company's debt-to-equity ratio indicates high leverage which poses a potential risk, but the positive stockholders' equity in 2025 is a significant improvement from previous negative values. The equity ratio is low, indicating a higher reliance on debt, but the return on equity is improving, suggesting better profitability management.

Cash Flow

Operating cash flow has shown improvement with positive trends, though free cash flow remains negative in recent years, highlighting potential liquidity challenges. The operating cash flow to net income ratio is strong, indicating efficient cash management relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.30B	6.00B	5.74B	4.98B	5.11B	3.87B
Gross Profit	3.26B	3.05B	2.65B	1.89B	2.04B	1.61B
EBITDA	926.84M	798.13M	985.49M	234.91M	1.13B	204.23M
Net Income	429.83M	305.30M	559.56M	-103.96M	814.74M	-126.06M
Balance Sheet
Total Assets	0.00	4.14B	3.43B	3.04B	3.53B	2.89B
Cash, Cash Equivalents and Short-Term Investments	129.60M	150.63M	34.00M	14.94M	226.56M	101.31M
Total Debt	0.00	1.77B	1.16B	1.09B	1.08B	2.04B
Total Liabilities	-592.72M	3.55B	3.16B	3.36B	3.76B	4.45B
Stockholders Equity	592.72M	592.72M	279.41M	-61.54M	-234.20M	-1.56B
Cash Flow
Free Cash Flow	0.00	-229.26M	-134.45M	71.69M	308.65M	122.53M
Operating Cash Flow	0.00	261.02M	39.78M	197.97M	405.23M	166.81M
Investing Cash Flow	0.00	-511.74M	-166.25M	-88.38M	5.87M	80.44M
Financing Cash Flow	0.00	257.33M	145.53M	-319.91M	-285.85M	-173.85M

Wanbury Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 235.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WANBURY, the sentiment is Neutral. The current price of 235.4 is above the 20-day moving average (MA) of 205.69, above the 50-day MA of 224.37, and below the 200-day MA of 255.16, indicating a neutral trend. The MACD of -10.56 indicates Negative momentum. The RSI at 50.17 is Neutral, neither overbought nor oversold. The STOCH value of 64.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:WANBURY.

Wanbury Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LINCOLN	74 Outperform	₹9.16B	11.46	―	0.37%	―	―
SAKAR	66 Neutral	₹8.58B	44.24	―	―	24.20%	55.01%
WANBURY	62 Neutral	₹7.27B	13.64	―	―	8.92%	-5.56%
KILITCH	57 Neutral	₹5.44B	18.55	―	―	32.95%	67.39%
KOPRAN	57 Neutral	₹6.19B	37.40	―	1.96%	-6.96%	-66.75%
THEMISMED	54 Neutral	₹7.41B	-27.46	―	0.48%	-18.86%	-150.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Wanbury Limited Corporate Events

Wanbury Begins Commercial Production of Key Anaesthetic API at Tanuku Plant

Wanbury Limited has started commercial production of a key high-potency anaesthetic API at its Tanuku facility in Andhra Pradesh, a milestone that marks the operationalisation of its new multi-purpose intermediate block. The company expects this launch, together with planned production of four additional high-value APIs (in antidiabetic, anticoagulant, antitussive and antidepressant segments) by March 2026, to generate incremental revenues of about Rs 100 crore in Q4 FY2025-26 and FY2026-27, strengthening its API portfolio and positioning it to capture robust global demand in a market estimated at over Rs 5,000 crore.

Wanbury Files EOGM Voting Results with NSE and BSE

Wanbury Limited has reported to the NSE and BSE the voting results of its Extraordinary General Meeting held on 5 January 2026, in compliance with SEBI’s Listing Obligations and Disclosure Requirements. The company disclosed shareholder participation figures, including total shareholders on record and attendance via video conferencing by promoter group and public shareholders, and submitted the scrutinizer’s report from an independent practicing company secretary, underscoring its adherence to prescribed corporate governance and disclosure norms.

Wanbury Limited Announces Virtual EGM for January 2026

Wanbury Limited has announced that it will hold an Extra Ordinary General Meeting (EGM) on January 5, 2026, through video conferencing or other audio-visual means. This meeting is in compliance with the guidelines issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The announcement is significant as it ensures shareholder engagement and compliance with regulatory standards, potentially impacting the company’s governance practices and stakeholder relations.

Wanbury Limited Awaited Response on Financial Results Clarification

Wanbury Limited has been asked by the Exchange to provide clarification regarding its financial results for the quarter ending September 30, 2025, as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has yet to respond to the request for clarification on why its consolidated financial results have not been submitted, which may impact its regulatory compliance and investor relations.

Wanbury Limited Allots Shares Under ESOP

Wanbury Limited announced the allotment of 15,000 equity shares to an eligible employee under its Employee Stock Option Plan 2016. This move, approved during the board meeting on November 13, 2025, will increase the company’s paid-up share capital slightly, reflecting a commitment to employee incentives and potentially impacting shareholder value.